Document is current
Any future updates will be listed below
-
Authors
Vlake, Johan H. https://orcid.org/0000-0002-0532-0252
Wils, Evert-Jan https://orcid.org/0000-0002-2868-0920
van Bommel, Jasper https://orcid.org/0000-0001-8408-0500
Gommers, Diederik https://orcid.org/0000-0001-6808-7702
van Genderen, Michel E. https://orcid.org/0000-0001-5668-3435
,
Korevaar, Tim I. M. https://orcid.org/0000-0001-7961-8791
Vlake, Paul W. J.
Hobers, Matilde
-
Funding
Funding for this research was provided by:
BeterKeten
- License Information
-
More Information
Article History
Accepted: 7 June 2022
First Online: 1 July 2022
Declarations
:
: DG has received speaker fees and travel expenses from Dräger, GE Healthcare (medical advisory board 2009–12), Maquet, and Novalung (medical advisory board 2015–18). TK has received speaker fees from Quidel, IBSA, Merck, Berlin Chemie, and Goodlife Healthcare. All other authors declare no competing interests.
: The study protocol was approved by the institutional review board of the Franciscus Gasthuis and Vlietland (local identification number: 2019-112), was found not to be subject to the Medical Research Involving Human Act, and the need for written informed-consent was waived due to the non-interventional and non-intrusive nature of the study and consent was implied by participation in the study.
: Not applicable.
